In vivo repression by a site-specific DNA-binding protein designed against an oncogenic sequence
- 15 December 1994
- journal article
- research article
- Published by Springer Nature in Nature
- Vol. 372 (6507) , 642-645
- https://doi.org/10.1038/372642a0
Abstract
A DNA-binding peptide comprising three zinc-fingers has been engineered to bind specifically to a unique nine-base-pair region of a BCR–ABL fusion oncogene in preference to the parent genomic sequences. Binding to the target oncogene in chromosomal DNA is possible in transformed cells in culture, and results in blockage of transcription. Consequently, murine cells rendered independent of growth factors by the action of the oncogene revert to factor dependence upon transient transfection with a vector expressing the peptide.Keywords
This publication has 37 references indexed in Scilit:
- Transcriptional repression directed by the yeast α2 protein in vitroNature, 1994
- GAL4 fusion vectors for expression in yeast or mammalian cellsGene, 1992
- Selection of phage antibodies by binding affinityJournal of Molecular Biology, 1992
- Sequence-specific DNA binding by a two zinc-finger peptide from the Drosophila melanogaster tramtrack proteinJournal of Molecular Biology, 1992
- Acute leukaemia in bcr/abl transgenic miceNature, 1990
- IL3-dependent mouse clones that express B-220 surface antigen, contain ig genes in germ-line configuration, and generate B lymphocytes in vivoCell, 1985
- Fused transcript of abl and bcr genes in chronic myelogenous leukaemiaNature, 1985
- An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activityCell, 1984
- Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22Cell, 1984
- Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemiaNature, 1983